AMAG Pharmaceuticals, Inc. (AMAG) to Release Quarterly Earnings on Tuesday

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is scheduled to announce its Q416 earnings results on Tuesday, February 14th. Analysts expect the company to announce earnings of $1.85 per share and revenue of $155.12 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 23.25 on Monday. The stock’s 50 day moving average is $26.51 and its 200-day moving average is $27.14. The stock has a market cap of $795.36 million, a price-to-earnings ratio of 53.45 and a beta of 1.09. AMAG Pharmaceuticals, Inc. has a 1-year low of $17.92 and a 1-year high of $36.83.

A number of brokerages have recently weighed in on AMAG. J P Morgan Chase & Co reiterated a “hold” rating and issued a $33.00 target price on shares of AMAG Pharmaceuticals in a report on Friday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and issued a $33.00 price target on shares of AMAG Pharmaceuticals in a research note on Wednesday, December 21st. Guggenheim initiated coverage on AMAG Pharmaceuticals in a research note on Monday, November 7th. They issued a “buy” rating and a $42.00 price target for the company. Leerink Swann cut AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $39.00 to $25.00 in a research note on Tuesday, January 10th. Finally, Needham & Company LLC cut AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $31.80.

ILLEGAL ACTIVITY WARNING: “AMAG Pharmaceuticals, Inc. (AMAG) to Release Quarterly Earnings on Tuesday” was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this article on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be viewed at http://sleekmoney.com/amag-pharmaceuticals-inc-amag-to-release-quarterly-earnings-on-tuesday/1657276.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

5 Day Chart for NASDAQ:AMAG

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/amag-pharmaceuticals-inc-amag-to-release-quarterly-earnings-on-tuesday/1657276.html

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *